Histology-Agnostic Drug Development — Considering Issues Beyond the Tissie
*Presagia AI (OccamPoint Partner member)The landmark approvals of pembrolizumab for the treatment of patients whose tumors have high microsatellite instability and larotrectinib and entrectinib for those harbouring NTRK fusions, have marked the beginning…
Read MoreOncolytic Viruses May Help Cancer Patients Overcome Resistance to Immunotherapy, Research Shows
Exciting research exploring ability of oncolytic viruses and commercially available anti-infectious disease vaccines to stimulate immune system response leading to increased potency of cancer immunotherapy. More
Read MoreFDA warns testing companies: Don’t tell patients how their DNA influences response to specific drugs
FDA imposes more scrutiny on efficacy and safety claims resulting from pharmacogenetics testing concerned about inappropriate use in patient care. More
Read MorePrecision Pathology as Part of Precision Medicine: Are We Optimizing Patients’ Interests in Prioritizing Use of Limited Tissue Samples?
Insufficient sample tissue and conflicting legal and regulatory requirements increasingly pose a practical obstacle for the implementation of precision medicine testing for patient treatment protocols and clinical trial research. While…
Read MoreLisa Suennen Reviews New Documentary at SxSW
What Jimmy Carter Owes to Jim Allison: When Breakthroughs Meet Reality A wonderful reflection by Lisa Suennen (Venture Valkyrie) on the movie documentary about the discovery of the check-point inhibitor…
Read More